Vered Caplan, Orgenesis CEO
January 20, 2022 09:04 AM EST
Manufacturing

Johns Hop­kins and lo­cal biotech team up for new man­u­fac­tur­ing site; New oral drug plat­form to help ac­cel­er­ate R&D time­line

Josh Sullivan

Johns Hop­kins Uni­ver­si­ty and a Mary­land-based biotech will join forces to de­vel­op a cell and gene ther­a­py pro­cess­ing fa­cil­i­ty at the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Ver­sant un­veils Light Horse with $62M and a part­ner­ship with No­var­tis

Af­ter lack­lus­ter 2024, bio­phar­ma in­dus­try prays stalled M&A will fi­nal­ly move in­to gear

Aio­los team re­unites with $411M for new biotech with obe­si­ty drugs from Chi­na

Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago

Cell ther­a­py start­up A2 Bio­ther­a­peu­tics nets $80M Se­ries C

Ley­den Labs gets $70M to test if nasal sprays can help pro­tect against virus­es

A service from the Financial Times